Peginterferon alfa-2a: all 237 studies that test it

Page 2 of 3. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous AngiosarcomaWithdrawnNCT05799612Phase 1
• Cemiplimab/Peg-Interferon-α in Advanced CSCCWithdrawnNCT05729139Phase 1
• Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver FibrosisStatus unknownNCT03957629Not applicable
• Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver FibrosisStatus unknownNCT03919565Not applicable
• Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2aCompletedNCT03719313Phase 3
• Evaluation of the Safety and Pharmacology of EYP001 in HBV SubjectsCompletedNCT03272009Phase 1
• The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by ResectionStatus unknownNCT03253250Phase 4
• The Changes of Cytokines During Antiviral TherapyStatus unknownNCT03210506Not applicable
• The Changes of Treg Cells Frequency and Function During Antiviral TherapyStatus unknownNCT03210493Not applicable
• The Changes of CD8+T Cells Frequency and Function During Antiviral TherapyStatus unknownNCT03209037Phase 4
• The Changes of CD4+T Cells Frequency and Function During Antiviral TherapyStatus unknownNCT03209011Phase 4
• The Changes of Natural Killer Cells Frequency and Function During Antiviral TherapyStatus unknownNCT03208998Phase 4
• The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCCStatus unknownNCT03084250Phase 4
• Peg-interferon for Inactive Chronic Hepatitis B CarriersCompletedNCT02992704Phase 2/3
• Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedNCT02992457Phase 4
• A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAsStatus unknownNCT02894918Phase 4
• A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal ImpairmentCompletedNCT02864199Phase 4
• Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) AdultsStatus unknownNCT02822547Phase 4
• A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6TerminatedNCT02791256Phase 3
• Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)TerminatedNCT02762383Phase 3
• HBsAg Loss Adding Pegylated Interferon in HBeAg-negative PatientsCompletedNCT02743182Not applicable
• Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPegCompletedNCT02742324Phase 1/2
• Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected PatientsCompletedNCT02646189Phase 1/2
• Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)IdesStatus unknownNCT02644538Phase 4
• A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)CompletedNCT02604823Phase 4
• A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis BCompletedNCT02598063Phase 4
• Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC TherapyCompletedNCT02594293Phase 4
• Switching Regimen in Treating Cirrhotic HCV GT1b SubjectsCompletedNCT02583685Phase 2
• A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver CancerCompletedNCT02576964Phase 2
• A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous AdministrationCompletedNCT02573025Phase 1
• A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)CompletedNCT02570191Phase 4
• An Exploratory Study of RGT Strategy on Optimal NUC-experienced PatientsStatus unknownNCT02560649Phase 4
• Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive PatientsStatus unknownNCT02474316Phase 4
• Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential ThrombocythemiaCompletedNCT02407080Phase 1
• Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV PatientsCompletedNCT02401737Phase 1
• Malaysia Stop Tyrosine Kinase Inhibitor TrialStatus unknownNCT02381379Phase 3
• Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute InfectionCompletedNCT02377856Phase 4
• Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B PatientsCompletedNCT02112799Phase 1
• An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue TherapyCompletedNCT02068365Phase 4
• Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNACompletedNCT01892241Phase 3
• Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy VolunteersCompletedNCT01889849Phase 1
• A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV InfectionCompletedNCT01846832Phase 3
• HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside MaintenanceStatus unknownNCT01769833Phase 3
• A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without CirrhosisCompletedNCT01749150Phase 2
• Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null RespondersCompletedNCT01725542Phase 2
• Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) TherapyCompletedNCT01718158Phase 3
• Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis CTerminatedNCT01639547Not applicable
• Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3CompletedNCT01616524Phase 3
• Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg LossStatus unknownNCT01599130Not applicable
• Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis CCompletedNCT01596517Phase 4
• Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)Status unknownNCT01589952Phase 1/2
• Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)CompletedNCT01573351Phase 3
• An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver TransplantationCompletedNCT01571583Phase 3
• 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS CWithdrawnNCT01517308Phase 3
• A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated CirrhosisCompletedNCT01516918Phase 2
• An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)CompletedNCT01513941Phase 3
• HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon TreatedCompletedNCT01471535Not applicable
• A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/mlStatus unknownNCT01464281Not applicable
• Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or RibavirinTerminatedNCT01425970Phase 2
• A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid NeoplasmsCompletedNCT01387763Phase 3
• PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B PatientsCompletedNCT01373684Phase 4
• Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT01371578Phase 2
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy SubjectsCompletedNCT01343186Phase 1
• Treatment of Recently Acquired Hepatitis C Virus InfectionCompletedNCT01336010Phase 4
• A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis CCompletedNCT01331850Phase 2
• A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)WithdrawnNCT01296971Phase 3
• A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)CompletedNCT01278134Phase 2
• Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.Status unknownNCT01272310Phase 1/2
• Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)CompletedNCT01259817Phase 2
• Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253CompletedNCT01237496Phase 3
• Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.CompletedNCT01195181Phase 4
• A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis BStatus unknownNCT01172392Phase 3
• Pegaferon and Ribavirin for Hepatitis CCompletedNCT01137383Phase 3
• A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedNCT01080222Phase 2
• PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)Status unknownNCT01056172Phase 4
• Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4CompletedNCT01006031Phase 2/3
• Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral LoadCompletedNCT00973219Not applicable
• A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous StudiesCompletedNCT00962975Phase 1
• Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis CCompletedNCT00948220Phase 4
• HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta HepatitisCompletedNCT00932971Phase 2
• Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis BStatus unknownNCT00921180Phase 4
• Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis BStatus unknownNCT00917761Phase 4
• Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis CCompletedNCT00917358Phase 4
• Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C InfectionCompletedNCT00911963Phase 1/2
• Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/RelapsersTerminatedNCT00882193Early Phase 1
• Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis BCompletedNCT00877760Phase 4
• A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis CCompletedNCT00800748Phase 4
• 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis CCompletedNCT00763568Phase 2
• Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 PatientsCompletedNCT00680173Phase 4
• Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and RibavirinTerminatedNCT00641654Phase 4
• Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular CarcinomaCompletedNCT00630084Phase 4
• A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 PatientsCompletedNCT00629967Phase 4
• Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis CCompletedNCT00629824Phase 4
• Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4CompletedNCT00612755Phase 4
• Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCVStatus unknownNCT00611819Phase 4
• Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis BStatus unknownNCT00597259Phase 4
• Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive PatientsWithdrawnNCT00571714Not applicable
• Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected PatientsCompletedNCT00553930Phase 4
• Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis CCompletedNCT00540345Phase 4
• Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis CCompletedNCT00527540Phase 3

← Peginterferon alfa-2a overview